Skip to main content
. Author manuscript; available in PMC: 2012 Dec 9.
Published in final edited form as: Vaccine. 2011 Oct 27;30(1):78–94. doi: 10.1016/j.vaccine.2011.10.040

Figure 1. Relative efficacy of Tev vaccines in macaques.

Figure 1

Figure 1

(A) The expression of Env, Nef, Rev, and Tev proteins was assessed by western blot in cell lysates at 4, 8, 14, and 18 hours post-transfection of the pHXB2 molecular clone in 293T cells.

(B) Amino acid sequence alignment of the putative HIVHXB2, HIVBa-L, HIVSF162, and HIV89.6 Tev proteins.

(C) HIVBa-L, HIVHXB2, HIVSF162, and HIV-189.6 Tev proteins expressed in HEK 293 cells. The Tev proteins produced by the cDNAs were identified using antibodies to Rev. The 89.6 Tev protein was purified from E. coli using a mouse anti-HIV-1 Tat column and separated on 10-20 % SDS-PAGE (right panel). Tev protein was recognized by Rabbit antibody to Rev (lane 1), but not with normal rabbit serum (lane 2). Molecular weight marker is shown in lane 3.

(D) Study design. The HIVBa-L, HIV89.6, and HIVSF162 Tev cDNAs were used in each DNA immunization, where “prot” stands for boosts with the purified HIV89.6 Tev protein. Challenge exposure to SHIV89.6P was performed via the intravenous route.

(E) Plasma virus levels in vaccinated and control macaques (left and center panels) following challenge exposure to SHIV89.6P. Right panel depicts mean level for both groups.

(F) CD4+ T-cell counts in vaccinated and control macaques (left and center panels) following challenge exposure to SHIV89.6P. Right panel depicts median level for both groups.